Truist initiated coverage of ArriVent Biopharma (AVBP) with a Buy rating and $43 price target ArriVent is advancing firmonertinib, an already China-approved and U.S. Breakthrough-designated inhibitor for hard-to-treat, mutation-driven lung cancers, with two global pivotal trials underway and topline FURVENT data expected in early 2026, the analyst tells investors in a research note. The company appears positioned for more than $1B peak sales potential and additional pipeline value not yet reflected in its share price, Truist argues.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVBP:
- ArriVent BioPharma, Inc.: Strategic Advancements and Promising Developments Drive Buy Rating with $45 Price Target
- ArriVent Biopharma management to meet virtually with Clear Street
- ArriVent Biopharma price target lowered to $31 from $33 at Citi
- ArriVent BioPharma Reports Q3 2025 Financial Results
- ArriVent BioPharma’s Promising Trial Results and Strategic Developments Drive Buy Rating